June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Exosomes for the treatment of keratoconus
Author Affiliations & Notes
  • Dimitrios Karamichos
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Dimitrios Karamichos None
  • Footnotes
    Support  NEI Grant EY030028-S1
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2447. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dimitrios Karamichos; Exosomes for the treatment of keratoconus. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2447.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : As the most common corneal ectasia, keratoconus (KC) is defined as bilateral and asymmetric corneal degeneration with localized corneal thinning and protrusion of the thinned cornea. KC affects approximately 1:400 to 1:2000 people worldwide. KC is the leading cause of corneal transplantation in western countries. It is a complex, multifactorial disorder with contributions from both genetic and environmental factors as well as biomechanical, metabolic, and hormonal factors. This session will provide key insights into corneal Extracellular Vesicles (EV) biology and their impact to KC pathobiology. Broad therapeutic implications and the potential to shift the paradigm on how KC is monitored/treated will also be discussed.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×